Swiss Pharma Company Novartis Has Received A Breakthrough Therapy Designation (Btd) For Its Experimental Medication Iptacopan For The Rare Blood Disorder Paroxysmal Nocturnal Hemoglobinuria (Pnh).The Therapy, Also Known As Lnp023, Was Also Awarded A Rare Paediatric Disease Designation At The Same Time For The Treatment Of C3 Glomerulopathy (C3G), A Group Of Ultra Rare Conditions That Can Cause End-Stage Renal Disease.Iptacopan Is An Oral Factor B Inhibitor And Is In Development Not Only For Pnh And C3G, But Also A Number Of Other Renal Conditions With Complement System Involvement.This Includes Iga Nephropathy (Igan), Atypical Hemolytic Uremic Syndrome (Ahus), And Membranous Nephropathy (Mn).The Btd Designation Was Based On The Positive Interim Results From Two Ongoing Phase 2 Studies, Within Which Iptacopan Demonstrated Benefits In Patients Who Remained Anaemic And Dependent On Transfusions, Despite Standard Of Care Anti-Complement Treatment, As Well As Monotherapy In Anti-C5 Naive Pnh Patients.In This Study, Iptacopan Significantly Reduced Proteinuria
